Pharmacy Podcast Network

DSCSA is Coming. Are you Ready? | Drug Topics

The Drug Supply Chain Security Act has been a decade in the making. Pharmacists must be prepared to comply by November 2023.The National Association of Boards of Pharmacy (NABP) has been working with state boards of pharmacy to update inspection standards and procedures, said Josh Bolin, associate executive director for Federal Affairs and Strategy at NABP. "After November 27, 2023, states will be unable to enact any tracing requirements that go beyond the obligations laid out in DSCSA but.. will check for DSCSA compliance", he noted, adding the "one of the open questions is enforcement discretion in the early period. We will continue to work with our partners as November grows closer." 

TWIRx | Children’s Book Feature

Children's Book Authors & Pharmacy Students Shay Roth & Jaccie Hisashima join "This Week in Pharmacy"  Jaccie Hisashima – University of Pittsburgh School of Pharmacy. Now completing a PGY1 Acute Care Residency at UC Davis Medical Center, Sacramento.Shay Roth, PharmD Candidate 2024 University of Pittsburgh School of Pharmacy, Co-Author and Illustrator

Exploring the Benefits and Stigma of CBD with Dr. Alex Capano | Sports Pharmacy Podcast

In this episode of the Sports Pharmacy Podcast, host Dr. H is joined by Dr. Alex Capano, a PhD in cannabinoid studies, to discuss the benefits and stigma surrounding CBD (cannabidiol). Dr. Alex shares her journey from neuroscience and chemistry studies to becoming a family nurse practitioner and eventually specializing in cannabis medicinally.The conversation delves into the importance of studying cannabis, destigmatizing its use, and providing patients with alternative therapeutic options to potentially harmful substances. Dr. H opens up about his personal connection to opioid alternatives, highlighting the need for better pain management solutions, especially in the world of sports.Dr. Alex emphasizes the responsible use of opiates when necessary but also highlights the potential of CBD and other cannabinoids in managing pain, particularly among athletes dealing with post-game pain or playing while injured. They discuss the experiences of professional athletes and the challenges they face in finding safe alternatives to manage pain and recover from injuries.

Psilocybin for Pain and TBI | Neural Pharm Podcast

Exploring the latest research on psilocybin for TBI and chronic pain
Adkins A and Ferguson MC. “Research update: MDMA and psilocybin for pain management.” Practical Pain Management. 18 June 2022. https://www.practicalpainmanagement.com/news/research-update-mdma-and-psilocybin-for-pain-management. Accessed 30 July 2023
Bornemann J, et al. “Self-medication for chronic pain using class psychedelics: A qualitative investigation to inform future research.” Frontiers in Psychiatry. 18 June 2022. https://www.practicalpainmanagement.com/news/research-update-mdma-and-psilocybin-for-pain-management Accessed 31 July 2023.
Fanciullacci M, et al. “Brief report: phantom limb pain: sub-hallucinogenic treatment with lysergic acid diethylamide (LSD).” Headache. 1977 July; 17(3): 118-119. https://pubmed.ncbi.nlm.nih.gov/893080/ Accessed 30 July 2023
Flanagan T, Nichols C. “Psychedelics as anti-inflammatory agents.” Psychedelic Research. 13 Aug 2018. Accessed 28 July 2023. https://blossomanalysis.com/papers/psychedelics-as-anti-inflammatory-agents/
Hawryluk M. “Pain, hope, and science collide as athletes turn to magic mushrooms.” WUSF Public Media. 30 Apr 2023. https://wusfnews.wusf.usf.edu/health-news-florida/2023-04-30/pain-hope-and-science-collide-as-athletes-turn-to-magic-mushrooms Accessed 30 July 2023.
Kooijman NI, et al. “Are psychedelics the answer to chronic pain: A review of current literature.” Pain Pract. 2023 Apr;23(4):447-458. Accessed 30 July 2023. doi: 10.1111/papr.13203. Epub 2023 Jan 11. PMID: 36597700.
“Lobe Sciences announces launch of pre-clinical study in collaboration with the University of Miami Miller School of Medicine.” Newsfile. 30 Nov 2020. Accessed 27 July 2023. https://www.newsfilecorp.com/release/69106/Lobe-Sciences-Announces-Launch-of-Preclinical-Study-in-Collaboration-with-the-University-of-Miami-Miller-School-of-Medicine
Made, Rachel. “Jim Harris was paralyzed. Then he ate magic mushrooms.” Outside. 9 Nov 2022. Accessed 27 July 2023. https://www.outsideonline.com/outdoor-adventure/exploration-survival/psychedelics-research-paralysis-treatment-jim-harris/
Mansoor Khan S, et al. “Psychedelics for brain injury: a mini review.” Frontiers in Neurology. 2021(12). 29 July 2021. Accessed 28 July 2023. https://www.frontiersin.org/articles/10.3389/fneur.2021.685085/full
Price S. “Data shows combination psilocybin therapy effective for TBI and PTSD.” Psychedelic Health UK. 30 Sept 2021. Accessed 30 July 2023. https://psychedelichealth.co.uk/2021/09/30/data-shows-combination-psilocybin-therapy-effective-for-tbi-and-ptsd/
Rauchman B. “UFC fighter’s brain injury successfully treated with psychedelic therapy.” Pacific Neuroscience Institute. 6 July 2023. Accessed 28 July 2023. https://www.pacificneuroscienceinstitute.org/blog/trip/ufc-fighters-brain-injury-successfully-treated-with-psychedelic-therapy/
Ramachandran V, et al. “Relief from intractable phantom pain by combining psilocybin and mirror visual feedback (MVF).” Neurocase. 2018 Apr; 24(2): 105-110. Accessed 29 July 2023. https://pubmed.ncbi.nlm.nih.gov/29764303/
Rosenhall U, et al. “Treatment of military acoustic accidents with n-acetyl-l-cysteine (NAC). Int J Audiology. 2019 March; 58(3): 151-157. Accessed 30 July 2023. https://pubmed.ncbi.nlm.nih.gov/30653365/
Schindler et al. “Exploratory investigation of a patient informed low dose psilocybin pulse regimen in the suppression of cluster headaches: results from a randomized, double-blind, placebo-controlled trial.” Headache. 23 Nov 2022. https://headachejournal.onlinelibrary.wiley.com/doi/abs/10.1111/head.14420 Accessed 30 July 2023.
“Traumatic Brain Injury and Concussion.” Centers for Disease Control. Last Reviewed: 7 July 2023. Last access 29 July 2023. https://www.cdc.gov/traumaticbraininjury/data/index.html

Sound Bites: Opill and Ozepmic | Sex PharmD

https://www.fda.gov/news-events/press-announcements/fda-approves-first-nonprescription-daily-oral-contraceptive

Holistic Support for Population Health through Intrapreneurship w/ Dr. Rohit Moghe | Holistic Pharmacy Podcast

Hello everyone, I’m super excited to release this next episode that was recorded at the start of this year. We covered so many topics near and dear to my personal and professional mission and I’m so honored to introduce my next guest and what he is contributing to healthcare. Dr. Rohit Moghe is an ambulatory care & population health clinical pharmacist for accountable care organization (ACO) at Trinity Health Mid-Atlantic. He is originally from the Philadelphia area. Dr. Moghe is a residency-training pharmacist with a master's in public health and a certified diabetes care & education specialist with over 22 years of experience across various therapeutic areas and whole continuum of care. Dr. Moghe is active in leadership at both Association of Diabetes Care & Education Specialists as well as American College of Lifestyle Medicine as Co-Chair of the pharmacist group. His diverse professional and life experience has led him to understand that most chronic conditions don't need to be managed with medications. However, if we must use them, we should be delivering comprehensive medication management (CMM) and get paid for the work that we do. His specialty is deprescribing medications, BUT, if they are to be ramped down, we must ramp up people's lifestyle. He uses the six pillars of lifestyle medicine: nutrition, enjoyable physical activity, restful sleep, addressing stress, reducing risky behaviors (& substances), and positive social connections. The stuff we should all optimize, but always pay enough attention to it. He focuses a lot on coaching his patients and clients through change. He is also a 200-hr yoga teacher registered through the Yoga Alliance and practices many forms of meditation and deep breathing exercises. Having grown up in yoga since an early age, application of Ayurvedic principles in his lifestyle come naturally to him, including appropriate use of herbal and natural remedies.

Do You Really Know What’s In Your Primary Vendor Agreement? | Pharmacy Crossroads

Tips for understanding and managing your wholesaler's primary vendor agreement.  Scott Patterson, owner of 6 pharmacies joins Scott Wittnebel, Director of Pharmacy Services for IPC talk about strategies and tactics you can use to maximize your rebates and lower you cost of goods.

Nectar Life Sciences & The Pharma Movie

Ken Chahine, founder and CEO at Nectar Life Sciences on your radar. Ken has a fascinating story: a child of immigrant parents, neither of whom finished elementary school, he earned a PhD in Biochemistry (U of Michigan) and a JD in patent law. 
After transforming the field of genetic testing for genealogy as General Manager of Ancestry DNA, he founded Nectar, a health tech company revolutionizing the allergy space with at-home allergy testing and treatment with sublingual drops.In grad school, Ken suffered from severe allergies that made lab work in goggles near-impossible. When he discovered the healthcare system’s solution for chronic allergy sufferers is constant medications (average = 3 meds per day) and/or painful, inconvenient shots, he knew there had to be a better way.Just a sample of what Ken can elaborate on:
First-hand experience with allergies as a chronic condition and advocating for the consumer 
Long-term benefits of at-home allergy testing + treatment
Why sublingual (under the tongue) treatment is already standard in Europe as a safer alternative to subcutaneous (shots)
How he transitioned into the allergy space after revolutionizing the genetic science behind Ancestry.com
Predictions for holistic approaches in the healthcare space

Talking Things Pharmacists Need to Know About Urine Drug Monitoring | Locked On Pharmacy

Controlled substances, including opioids, benzodiazepines, and medical cannabis, are commonly prescribed for the treatment of chronic pain. Urine drug screens (UDS) are often used in clinical practice to test for the presence of prescribed drugs to monitor compliance. Understanding how to appropriately interpret the results of urine drug screening is critical to providing effective patient care and maintaining patient trust. Pharmacists in various practice settings can play important roles in urine drug screenings.
The goal of this podcast is to provide pharmacists and other clinicians with insight and information for appropriately interpreting urine drug screening results. The conversation will focus on the types of drug screening panels, possible causes of false- positives and negatives, and how metabolism of drugs can impact urine drug screening results. Tips on how to effectively have conversations with patients that can be difficult will also be part of the discussion.
This activity is supported by a grant from the Providers Clinical Support System (PCSS).Funding for this initiative was made possible (in part) by grant no. 6H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
 
 

Why Rare-Ultra Orphan Therapies need early Market Access planning and innovative solutions | Ascella Health

Success in launching new therapies for rare diseases (RDs) implies the ability for the manufacturer to achieve a level of reimbursed price and a level of market access that are commercially viable on the market. Access to RD therapies is challenging because the legal and policy frameworks may be absent, funding may be insufficient and/or payers do not see the justification with the prices for these therapies. The industry has, however, a real opportunity to partner with healthcare stakeholders.  There needs to be continued support to provide the education towards payers, drive evidence-based pricing, and innovative contracting, and address the multiple hurdles of access for these unique therapies. But how do we price and how do we gain access on the promise of long-term value when we don’t have the long-term data on these new therapies?  That is why all stakeholders need to address early market access planning, including inclusive data collection, payer models and the impact of new regulations and innovative trial design on data collection and ongoing evidence provision.
           
Podcast Participants: Jim Clement – Partner & Board Member at Coeus Holdings
                                       Donovan Quill – Executive Vice President at Terebellum